Walleye Capital’s Corcept Therapeutics CORT Stock Holding History

Walleye Capital’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$40.3K	Sell	1,000 -179,401	-99%	-$6.71M	﹤0.01%	3947
2025 Q4	$6.28M	Buy	180,401 +180,080	+56,100%	+$14.1M	0.02%	978
2025 Q3	$26.7K	Sell	321 -1,711	-84%	-$124K	﹤0.01%	4160
2025 Q2	$149K	Buy	+2,032	New	+$147K	﹤0.01%	3564
2025 Q1	–	Sell	-460	Closed	-$28K	–	4367
2024 Q4	$23.2K	Buy	+460	New	+$24.1K	﹤0.01%	4483
2024 Q3	–	Sell	-13,189	Closed	-$429K	–	5380
2024 Q2	$429K	Buy	+13,189	New	+$361K	﹤0.01%	3640
2021 Q3	–	Sell	-23,514	Closed	-$517	–	1627
2021 Q2	$517	Buy	+23,514	New	+$523K	0.02%	735
2020 Q1	–	Sell	-17,174	Closed	-$207K	–	1045
2019 Q4	$207K	Buy	+17,174	New	+$239K	0.01%	1094

Other funds holding CORT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Walleye Capital's CORT Position: Q1 2026 in Review

Walleye Capital reduced its Corcept Therapeutics (CORT) stake by 99% in Q1 2026, selling an estimated $6.71M and leaving 1,000 shares worth $40.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3947.

Walleye Capital first reported a position in CORT in Q4 2019 and has held it in 8 quarters since. The position peaked at $6.28M in Q4 2025. 351 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

Walleye Capital held 1,000 shares of Corcept Therapeutics worth $40.3K as of Q1 2026.
Walleye Capital sold 179,401 Corcept Therapeutics shares in Q1 2026, an estimated $6.71M.
Corcept Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #3947 holding.
Walleye Capital first reported a position in Corcept Therapeutics in Q4 2019 and has held it in 8 quarters since.
Walleye Capital's Corcept Therapeutics position peaked at $6.28M in Q4 2025.
351 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.